Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity
Yap, Timothy A., Luken, Maria J. de Miguel, O'Carrigan, Brent, Roda, Desam, Papadatos-Pastos, Dionysis, Lorente, David, Tunariu, Nina, Lopez, Raquel Perez, Gayle, Sasha, Riisnaes, Ruth, Figueiredo, Ines, Miranda, Susana, Carreira, Suzanne, Yang, Fang, Karan, Sharon, Penney, Marina, Pollard, John, Molife, L. Rhoda, Banerji, Udai, Asmal, Mohammed, Fields, Scott Z., Bono, Johann S. de
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article